Short-term proof-of-principle trial of ripirivine (TMC278) in patients with HIV-1 infections who previously failed antiretroviral therapy

Trial Profile

Short-term proof-of-principle trial of ripirivine (TMC278) in patients with HIV-1 infections who previously failed antiretroviral therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Rilpivirine (Primary) ; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top